Pivotal bioVenture Partners Investment Advisor LLC
In its 13F for Q2 2024 (holdings as of June 30, 2024, filed August 13, 2024), Pivotal bioVenture Partners Investment Advisor LLC reported 10 stock positions worth $130.1 million. Its top holding was Vaxcyte (PCVX) at 46.0% of the portfolio, followed by Inozyme Pharma (INZY, 15.4%) and Oculis (OCS, 14.7%). Compared with Q1 2024, it sold out of 1 and added to 1. The biggest buy was Arcutis Biotherapeutics (ARQT, shares +1%) and the biggest sale an exit from Fusion Pharmaceuticals (FUSN).
- Most Recent 13F
- Q2 2026
- Location
- SAN FRANCISCO, CA
- CIK
- 0001844645
- Portfolio Value
- $130.1M (Q2 2024)
- SEC Filing
- 0001012975-24-000321 ↗ filed Aug 13, 2024
Holdings Value
Holdings 10 stocks · $130.1M
| PCVX Vaxcyte Inc. | 46.04% | 793,036 | $59.9M | No change |
| INZY Inozyme Pharma Inc. | 15.41% | 4,494,851 | $20.0M | No change |
| OCS Oculis Holding AG | 14.66% | 1,595,918 | $19.1M | No change |
| ARQT Arcutis Biotherapeutics Inc. | 14.59% | 2,041,108 | $19.0M | Add +0.7% |
| EXAI Exscientia Ltd. | 3.02% | 770,500 | $3.9M | No change |
| RLYB Rallybio Corp. | 2.48% | 2,404,644 | $3.2M | No change |
| VIGL Vigil Neuroscience Inc. | 1.72% | 560,595 | $2.2M | No change |
| BOLT Bolt Biotherapeutics Inc. | 1.09% | 1,891,467 | $1.4M | No change |
| IOBTQ Io Biotech Inc. | 0.78% | 864,197 | $1.0M | No change |
| ALGS Aligos Therapeutics Inc. | 0.20% | 743,215 | $260K | No change |
Portfolio Sells Q1 2024 → Q2 2024
| FUSN Fusion Pharmaceuticals Inc. | Sold out | 0.00% | −7.72 |
Portfolio Buys Q1 2024 → Q2 2024
| ARQT Arcutis Biotherapeutics Inc. | Add +0.7% | 14.59% | +1.68 |
All Filings
| Quarter | Positions | 13F Reported Value | Top Holdings |
|---|---|---|---|
| Q2 2026 | 13 | $307.8M | PCVX, ARQT, TRVI, AVLN, EVMN |
| Q1 2026 | 13 | $279.8M | PCVX, OCS, EVMN, ARQT, TRVI |
| Q4 2025 | 12 | $258.7M | PCVX, OCS, ARQT, EVMN, ZBIO |
| Q3 2025 | 10 | $173.0M | PCVX, OCS, ARQT, ZBIO, TRVI |
| Q2 2025 | 12 | $161.3M | OCS, PCVX, ARQT, INZY, ZBIO |
| Q1 2025 | 11 | $123.6M | OCS, ARQT, PCVX, ZBIO, INZY |
| Q4 2024 | 11 | $148.1M | PCVX, OCS, ARQT, INZY, ZBIO |
| Q3 2024 | 11 | $168.5M | PCVX, INZY, ARQT, OCS, ZBIO |
| Q2 2024 | 10 | $130.1M | PCVX, INZY, OCS, ARQT, EXAI |
| Q1 2024 | 11 | $155.6M | PCVX, INZY, ARQT, OCS, FUSN |